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Abstract: Diffuse large B-cell lymphoma is the commonest histological type of malignant lymphoma, and
remains incurable in many cases. Developing more efficient immunotherapy strategies will require better
understanding of the disorders of immune responses in cancer patients. NKT (natural killer-like T) cells were
originally described as a unique population of T cells with the co-expression of NK cell markers. Apart from
their role in protecting against microbial pathogens and controlling autoimmune diseases, NKT cells have
been recently revealed as one of the key players in the immune responses against tumors. The objective of this
study was to evaluate the frequency of CD3+/CD16+CD56+ cells in the peripheral blood of 28 diffuse large
B-cell lymphoma (DLBCL) patients in correlation with clinical and laboratory parameters. Median percent-
ages of CD3+/CD16+CD56+ were significantly lower in patients with DLBCL compared to healthy donors
(7.37% vs. 9.01%, p = 0.01; 4.60% vs. 5.81%, p = 0.03), although there were no differences in absolute counts.
The frequency and the absolute numbers of CD3+/CD16+CD56+ cells were lower in advanced clinical stages
than in earlier ones. The median percentage of CD3+/CD16+CD56+ cells in patients in Ann Arbor stages 1–2 was
5.55% vs. 3.15% in stages 3–4 (p = 0.02), with median absolute counts respectively 0.26 G/L vs. 0.41 G/L (p =
= 0.02). The percentage and absolute numbers of CD3+/CD16+CD56+ cells were significantly higher in DL
-BCL patients without B-symptoms compared to the patients with B-symptoms, (5.51% vs. 2.46%, p = 0.04;
0.21 G/L vs. 0.44 G/L, p = 0.04). The percentage of CD3+/CD16+CD56+ cells correlated adversely with serum
lactate dehydrogenase (R= –445; p < 0.05) which might influence NKT count. These figures suggest a relation-
ship between higher tumor burden and more aggressive disease and decreased NKT numbers. But it remains to
be explained whether low NKT cell counts in the peripheral blood of patients with DLBCL are the result of their
suppression by the tumor cells, or their migration to affected lymph nodes or organs. (Folia Histochemica et
Cytobiologica 2011; Vol. 49, No. 1, pp. 183–187)
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Introduction
Non-Hodgkin’s lymphoma (NHL) is a heterogeneous
group of malignancies derived from lymphoid system
cells. They follow different clinical courses and prog-184 I Hus et al.
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noses depending on the type of malignant cells, the
degree of their differentiation, and their location
in lymphoid structures. B-cell lymphoma compri-
ses about 86% of all lymphomas, with diffuse large
B-cell lymphoma (DLBCL) being the commonest his-
tological type. Immunochemotherapy with mono-
clonal antibodies is nowadays the most effective meth-
od of NHL therapy [1, 2], although in many cases the
disease remains incurable. The key to developing
new, more efficient immunotherapy strategies is
better understanding of the disorders of immune
responses in cancer patients. In malignant lympho-
mas, interactions between tumor cells and immune
cells are different and much more complex than in
solid tumors, since malignant cells themselves be-
long to the immune system. In recent years, new
populations of T helper cells have been described,
and their role in tumor immunity is still only partly
understood. NKT cells constitute a unique popula-
tion of T cells with the co-expression of NK cell
markers such as NK1.1. (NKRP1C; CD161) and
Ly49 [3–5]. In contrast to CD4 and CD8 T cells,
NKT cells recognize lipid antigens in the context of
the major histocompatibility complex (MHC) class
I-like antigen presenting molecule CD1d [6, 7].
Upon TCR activation, they rapidly produce large
amounts of both pro- and anti-inflammatory cytoki-
nes, such as: IL-2, IFN-g, TNFa and IL-4 [8]. NKT
cells are divided into two populations, invariant NKT
cells (iNKT, type I NKT) which express invariant
TCR using Va14-Ja281 a-chain in mice and Va24-
-JaQ in humans, and variant NKT (type II NKT) with
a more diverse TCR repertoire. NKT cells have been
shown to play a role in numerous immune responses,
including protection against microbial pathogens [3, 9]
and control of autoimmune diseases [3]. Moreover,
iNKT cells have been recently revealed to be one of
the key players in immune responses against tumors.
CD3+/CD16+CD56+ T cells are not classical invari-
ant NKT cells, but are a broader group of T cells
matching the original definition of NKT cells [4, 5].
Since there is only limited data on the role of NKT-
-like cells in malignant lymphomas, the objective of
this study was to evaluate the frequency of NKT-like
cells in the peripheral blood of DLBCL patients in
correlation with clinical and laboratory parameters.
Material and methods
Patients and samples
Peripheral blood (PB) samples were collected from
28 patients diagnosed with DLBCL between August
2008 and February 2010 (13 men and 15 women).
The samples were taken at diagnosis, before the start
of any anti-cancer therapy. The median age of pa-
tients was 64 years (range 36 to 80 years). At the time
of diagnosis, patients were assessed according to the
Ann Arbor classification as follows: stage 1 — three
patients, stage 2 — six patients, stage 3 — seven pa-
tients, stage 4 — 12 patients. B-symptoms were
present in 12 patients. Control samples of PB were
obtained from 20 healthy volunteers (8 men and 12
women aged from 33 to 66 years, median age 58
years). PB samples were collected into heparinized
tubes and immediately processed. The study was ap-
proved by the Local Ethical Committee. Peripheral
blood samples were obtained from the patients and
healthy volunteers after informed consent.
Assessment of CD3+/CD16+CD56+ cells
Percentages of NKT-like cells were evaluated with
flow cytometry using monoclonal antibodies (MoAbs)
anti-CD3 FITC/CD16+CD56 PE/CD45 PerCP (BD
Biosciences), which allowed for simultaneous assessment
of T (CD3+) lymphocytes and NK (CD16+CD56+) cells.
During analysis, the CD3+/CD16+CD56+ population
was determined. A standard, whole-blood assay with
erythrocyte cell lysis was used to prepare the PB sam-
ples. The samples were analyzed by flow cytometry
directly after preparation. For data acquisition and
analysis, a FACSCalibur instrument (BD) with
CellQuest software (BD) was used. For each analy-
sis, 10,000 events were acquired and analyzed. The
percentage of positive cells was measured from a cut-
-off set using isotype matched nonspecific control anti-
body. CD3+/CD16+CD56+ T cells were analyzed with-
in gated CD45+ cells as well as CD3+ T lymphocytes.
Statistical analysis
The statistical significance of the observed differenc-
es was deduced by means of the Mann–Whitney U
test. Spearman rank test was used to assess correla-
tion between the variables. We used Statistica 7.0 PL
software for all statistical procedures. Differences
were considered as statistically significant when the
p value was £ 0.05.
Results
Median percentages of CD3+/CD16+CD56+ cells
within CD3+ T lymphocytes and within CD45+ cells
were significantly lower in patients with DLBCL com-
pared to healthy donors (7.37% vs. 9.01%, p = 0.01;
4.60% vs. 5.81%, p = 0.03). Median absolute count of
CD3+/CD16+CD56+ cells was also lower in DL-BCL
patients compared to the healthy controls (0.2 G/L
vs. 0.43 G/L; p = 0.04) (Figures 1A–C).185 CD3+/CD16+CD56+ cells in diffuse large B-cell lymphoma
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The frequency of CD3+/CD16+CD56+ cells de-
creased with the stage of disease. The median per-
centage of CD3+/CD16+CD56+ cells within CD3+
cells was 8.14% in patients in stages 1 and 2 and
5.81% in stages 3 and 4 (p = 0.07). Within CD45+
cells, the frequencies were 5.55% and 3.15%, respec-
tively (p = 0.02). Median absolute count of CD3+/
/CD16+CD56+ cells was also lower in more advanced
stages compared to earlier ones (0.26 G/L vs. 0.41 G/
/L; p = 0.02) (Figures 2A–C).
The percentage of CD3+/CD16+CD56+ cells
was significantly higher in DLBCL patients without
B-symptoms compared to patients with B-symptoms,
both within CD3+ cells (8.70% vs. 4.89%; p = 0.03),
and within CD45+ cells (5.51% vs. 2.46%; p = 0.04).
Median absolute count of CD3+/CD16+CD56+
cells was also significantly lower in the patients with
B-symptoms (0.21 G/L vs. 0.44 G/L; p = 0.04) (Figu-
res 3A–C).
Figure 1. NKT-like (CD3+/CD16+CD56+) numbers in
patients with DLBCL and healthy controls
Figure 2. NKT-like (CD3+/CD16+CD56+) numbers in
patients in early and advanced stages of disease186 I Hus et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0025
www.fhc.viamedica.pl
Percentage of CD3+/CD16+CD56+ cells correla-
ted adversely with lactate dehydrogenase (R = –445;
p < 0.05).
Discussion
Hopes for an improved prognosis for cancer patients
are associated with cellular immunotherapy, which
involves the elimination of tumor cells using the pa-
tient’s own immune mechanisms. Recent studies have
demonstrated encouraging preclinical results of NKT
cell based anti-cancer immunotherapy. Activated
iNKT cells may destroy tumor cells, both directly and
indirectly. Directly, they exert a cytotoxic effect
through expression of effector molecules that induce
cell death, such as perforin, FasL and TRAIL. Indi-
rectly, through the secretion of cytokines, especially
Th1 and cell-to-cell contact, they stimulate innate and
acquired immune cell types involved in the anti-can-
cer response [10–12]. Experimental studies have
shown that presented in the context of CD1d, syn-
thetic molecule aGal-Cer strongly stimulates both the
immediate and direct anti-tumor effects of human
and murine iNKT cells [13, 14]. NKT cell numbers
are decreased in the peripheral blood of patients with
solid tumors such as melanoma, prostate or lung can-
cer [15–18], but opinions on their activity diverge, with
some authors showing impaired [17, 19, 20], and oth-
ers normal, function [15, 18].
In our study, we found lower frequencies of NKT
cells in peripheral blood patients with DLBCL, but
absolute counts of CD3+/CD16+CD56+ were com-
parable to the healthy controls. Molling et al. in
a study group of 120 cancer patients found on aver-
age 47% fewer iNKT cells compared to healthy sub-
jects [21], regardless of the type of tumor or tumor
mass. The number of NKT cells did not increase af-
ter removal of the tumor by surgery or radiotherapy
[21]. The authors concluded that a reduced number
of circulating NKT cells secreting IFN-Va24/Vb11
could therefore be a risk factor for developing cancer
rather than a result of the presence of a tumor. In
contrast, we noted significantly lower counts of CD3+/
/CD16+CD56+ in DLBCL patients in more advanced
clinical stages, which indicates that higher tumor bur-
den might influence NKT count. Moreover, the
CD3+/CD16+CD56+ cell percentage was lower in
patients with poor prognostic factors like the presence
of B-symptoms and adversely correlated with LDH
serum level, which indicates a relationship between
a more aggressive form of the disease and a decrease
of NKT numbers.
It is still to be explained whether low NKT cell
counts in peripheral blood of patients with DLBCL
results from their suppression by the tumor cells or
their migration to affected lymph nodes or organs.
Yoneda et al. found a relationship between NKT cell
numbers and tumor mass. They found decreased
Va24+NKT cell numbers in patients with hemato-
poietic malignancies, including malignant lymphoma.
All studied NHL patients were previously treated with
chemotherapy, and NKT cells were decreased only
in patients with progressive disease, not in patients
in remission. Such conflicting data might result from
the small number and diversity of patient groups, but
Figure 3. NKT-like (CD3+/CD16+CD56+) numbers in
DLBCL patients without B-symptoms and patients with
B-symptoms187 CD3+/CD16+CD56+ cells in diffuse large B-cell lymphoma
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also from different methods of NKT cell evaluation.
Our study measured CD3+/CD16+CD56+ cells, but
both Molling et al. and Yoneda et al. evaluated
Va24+NKT cells. It seems that different subpopula-
tions of NKT might play distinct roles in tumor im-
munity [22]. Renukaradhya et al. showed that type I
NKT cells protect, and type II NKT cells suppress,
innate anti-tumor responses to a B-cell lymphoma
[23]. Yoneda et al. postulated that CD4–CD8–
–Va24+NKT cells are more dominantly involved in
activating tumor immunity [22]. It is entirely possible
that the function of immune cells might differ accord-
ing to differing types of lymphoma.
Results of preclinical studies suggest a potential
use of NKT cells in patients with lymphoma. Bag-
nara et al. demonstrated in a SCID mouse model that
adoptive transfer of expanded ex vivo NKT cells to-
gether with a-GalCer resulted in reduction of tumor
size (inoculated C1R-CD1d lymphoma cell line) [24].
Guven et al. showed that CD3+/CD16+CD56+ cells
from peripheral blood of patients with chronic lym-
phocytic leukemia could be easily expanded in in vit-
ro cultures and that these cells had cytotoxic activity
[25]. However, these results are only preliminary, so
it will be of great importance to determine the func-
tion of distinct NKT subsets in malignant lymphoma.
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